GSK Opens First U.S. Vax R&D Center

Dec 14, 2016

GSK has opened its newest global vaccines R&D center -- the drugmaker's first fully dedicated vaccines R&D center located in the US. -- in Rockville, Maryland.

The new facility will create up to 200 new jobs, with GSK investing over $50 million in the next two years to continue to develop the site with latest state-of-the-art scientific research technology and equipment.

The facility will house a total of 12 critical vaccine development programs, including projects supporting GSK's candidate shingles vaccine, which was filed for approval with the US FDA in October 2016. Additionally, R&D programs for respiratory syncytial virus (RSV), a major cause of respiratory infections in young children and the elderly, Group B Streptococcus (GBS), a bacterial infection affecting newborns, and dengue fever will be based at the site.

Read the GSK press release


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments